Emerging tier · Skin & Complexion
Rapamycin for Skin & Complexion
An mTOR inhibitor FDA-approved as an immunosuppressant, now studied for longevity applications.
Medical Disclaimer
Why Rapamycin for Skin & Complexion
Role in Protocol
mTOR inhibition for skin aging
Evidence Note
A pilot study showed topical rapamycin improved clinical markers of skin aging (reduced wrinkles, improved skin tone). Mechanism involves enhanced collagen production and reduced senescent cell burden. Larger trials are needed.
Dosing Context
Longevity (Intermittent)
Dose
1–6 mg
Frequency
weekly
Transplant Immunosuppression (FDA-Approved)
Dose
2–15 mg
Frequency
daily
Often Used Alongside
Key Safety Notes
Hypersensitivity to sirolimus or derivatives
Allergic reactions documented.
Active untreated infections
Immunosuppressive at transplant doses; even at low doses, immune function is modulated.
Severe hepatic impairment
Rapamycin is hepatically metabolised via CYP3A4.
Full Rapamycin Profile →
Full Skin & Complexion Protocol →